REFERENCES:
1. Matsumura N, Shiiki H, Nishino T, Dohi K. Unusual Case of Membranous Nephropathy Exhibiting Type III Collagen Microfibrils. Nephron 1998; 80(1): 104-105.
2. Arora MK, Reddy K, Balakumar P. The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy. Eur J Pharmacol 2010; 636(1-3): 137-144.
3. Pazhayattil GS, Shirali AC. Drug-induced impairment of renal function. Int J Nephrol Renovasc Dis 2014; 7: 457-468.
4. Hendriks JG, vanHorn JR, van der Mei, H.C., Busscher, H.J., 2004. Backgrounds of antibiotic-loaded bone cement and prosthesis-related infection. Biomaterials 2014; 25(3): 545-556.
5. Chen S, Hong S, Iglesias-de la Cruz MC, Isono M, Casaretto A, Ziyadeh F. The key role of the transforming growth factor-β system in the pathogenesis of diabetic nephropathy. Ren Fail 2001; 23(3-4): 471-481.
6. Stangou M, Bhangal G, Lai PC, Smith J, Keith JC Jr, Boyle JJ, et al. Effect of IL-11 on glomerular expression of TGF-beta and extracellular matrix in nephrotoxic nephritis in Wistar Kyoto rats. J Nephrol 2011; 24(1): 106-111.
7. Ling XC, Kuo KL. Oxidative stress in chronic kidney disease. Ren Replace Ther 2018; 4: 53.
8. Prabhakar SS. Pathogenic role of nitric oxide alterations in diabetic nephropathy. Curr Diab Rep 2005; 5(6): 449-454.
9. Geleilete TJ, Melo GC, Costa RS, Volpini RA, Soares TJ, Coimbra TM. Role of myofibroblasts, macrophages, transforming growth factor-beta endothelin, angiotensin-II, and fibronectin in the progression of tubulointerstitial nephritis induced by gentamicin. J Nephrol 2002; 15(6): 633-642.
10. Hur E, Garip A, Camyar A, Ilgun S, Ozisik M, Tuna S, et al. The effects of vitamin D on gentamicin-induced acute kidney injury in experimental rat model. Int J Endocrinol 2013: 1-7.
11. Carr W, Schaeffer J, Donnenfeld E. Treating allergic conjunctivitis: A once-daily medication that provides 24-hour symptom relief. Allergy Rhinol (Providence) 2016; 7(2): 107-114.
12. Reddy JM, Reddy VMP, Dass RBR. The novel role of mast cell stabilizer in halting the development of nephropathy in diabetic rats: Implication of resident renal mast cells. ICMBPS 2012: 84-89.
13. Perse M., Veceric-Haler Z. Cisplatin-induced rodent model of kidney injury: Characteristics and challenges. Biomed Res Int 2018: 1462802.
14. Cheng CF, Chen HH, Lin H. Role of PPARα and its agonist in renal diseases. PPAR Res 2010: 345098-345098.
15. Finco DR, Duncan JR. Evaluation of blood urea nitrogen and serum creatinine concentrations as indicators of renal dysfunction: A study of 111 cases and a review of related literature. J Am Vet Med Assoc 1976; 168(7): 593-601.
16. Taussky HH, Bonsnes RW. On the colorimetric determination of creatinine by the jaffe reaction. J Biol Chem 1945; 158: 581.
17. Fawcett JK, Scott JE. A rapid and precise method for the determination of urea. J Clin Path 1960; 13: 156-159.
18. Watanabe N, Kamei S, Ohkubo A, Yamanaka M, Ohsawa S, Makino K, et al. Urinary protein as measured with a pyrogallol red-molybdate complex, manually and in a Hitachi 726 automated analyzer. Clin Chem 1986; 32(8): 1551-4.
19. Penumarthy S, Penmetsa GS, Mannem S. Assessment of serum levels of triglycerides, total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol in periodontitis patients. J Indian Soc Periodontol 2013; 17(1): 30-35.
20. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982; 28(10): 2077-2080.
21. Allain C, Poon LS, Chan CSG, Wy R, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20(4): 470-5.
22. Crowell JA, Korytko PJ, Morrissey RL, Booth TD, Levine BS. Resveratrol-associated renal toxicity. Toxicol Sci 2004; 82(2): 614-619.
23. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95(2): 351-358.
24. Udupa V, Prakash V. Gentamicin induced acute renal damage and its evaluation using urinary biomarkers in rats. Toxicol Rep 2018; 6: 91-99.
25. Ratliff BB, Abdulmahdi W, Pawar R, Wolin MS. Oxidant mechanisms in renal injury and disease. Antioxid Redox Signal 2016; 25(3): 119-146.
26. Amin K. The role of mast cells in allergic inflammation. Respir Med 2012; 106(1): 9-14.
27. Naclerio R. Clinical manifestations of the release of histamine and other inflammatory mediators. J Allergy Clin Immunol 1999; 103(3): S382–S385.
28. Holdsworth SR, Summers SA. Role of mast cells in progressive renal diseases. J Am Soc Nephrol 2008; 19(12): 2254-2261.
29. He A. Shi GP. Mast cell chymase and tryptase as targets for cardiovascular and metabolic diseases. Curr Pharm Des 2013; 19(6): 1114-1125.
30. Ward DT, McLarnon SJ, Riccardi D. Aminoglycosides increase intracellular calcium levels and ERK activity in proximal tubular OK cells expressing the extracellular calcium-sensing receptor. J Am Soc Nephrol 2002; 13(6): 1481-89.
31. Ghaznavi H, Mehrzadi S, Dormanesh B, Tabatabaei SMTH, Vahedi H, Hosseinzadeh A, et al. Comparison of the protective effects of melatonin and silymarin against gentamicin-induced nephrotoxicity in rats. J Evid Based Complementary Altern Med 2016; 21(4): NP49-NP55.
32. Sinniah A, Yazid S, Flower RJ. The anti-allergic cromones: Past, present, and future. Front Pharmacol 2017; 8: 827.
33. Kennedy LL, Hargrove LA, Graf AB, Francis TC, Hodges KM, Nguyen QP, et al. Inhibition of mast cell-derived histamine secretion by cromolyn sodium treatment decreases biliary hyperplasia in cholestatic rodents. Lab Invest 2014; 94(12): 1406-1418.
34. Gyebi L, Soltani Z, Reisin E. Lipid nephrotoxicity: new concept for an old disease. Curr Hypertens Rep 2012; 14(2): 177-181.
35. Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol 2018; 14(1): 57-70.
36. Ortega-Velazquez R, Gonzalez-Rubio M, Ruiz-Torres MP, Diez-Marques ML, Iglesias MC, Rodriguez-Puyol M, et al. Collagen I upregulates extracellular matrix gene expression and secretion of TGF-beta 1 by cultured human mesangial cells. Am J Physiol Cell Physiol 2004; 286(6): C1335-1343.
37. Chen HH, Sue YM, Chen CH, Hsu YH, Hou CC, Cheng CY, et al. Peroxisome proliferator-activated receptor alpha plays a crucial role in L-carnitine anti-apoptosis effect in renal tubular cells. Nephrol Dial Transplant 2009; 24(10): 3042-3049.
38. Hong YA, Lim JH, Kim MY, Kim TW, Kim Y, Yang KS, et al. Fenofibrate improves renal lipotoxicity through activation of AMPK-PGC-1alpha in db/db mice. PLoS One 2014; 9(5): e96147.
39. Ibrahim MA, El-Sheikh AA, Khalaf HM, Abdelrahman AM. Protective effect of peroxisome proliferator activator receptor (PPAR)-α and -γ ligands against methotrexate-induced nephrotoxicity. Immunopharmacol Immunotoxicol 2014; 36(2): 130-137.
40. Matsushita Y, Ogawa D, Wada J, Yamamoto N, Shikata K, Sato C, et al. Activation of peroxisome proliferator-activated receptor delta inhibits streptozotocin-induced diabetic nephropathy through anti-inflammatory mechanisms in mice. Diabetes 2011; 60(3): 960-968.
41. Protasov K, Fedorishina O, Dzizinsky A, Antonenko N. Renoprotective effect of the lisinopril and amlodipine fixed combination in patients with arterial hypertension and diabetes mellitus. J Hypertens 2011; 29: e405.